Breast cancer progression may be halted with CRISPR gene editing
A tumour-targeted CRISPR gene editing system encapsulated in a nanogel could halt the growth of triple-negative breast cancer.
List view / Grid view
A tumour-targeted CRISPR gene editing system encapsulated in a nanogel could halt the growth of triple-negative breast cancer.
TSKgel FcR-IIIA-NPR is based on a recombinant FcγIIIa receptor ligand immobilized on a non-porous polymer particle. It allows fast assessment of biologic activity of monoclonal antibodies.
Researchers have discovered a subtype of immune cells that contribute to allergic reactions and anaphylaxis, providing a drug target.
New study shows that a subset of follicular helper T cells contributes to the hyposialylation of autoantibodies in rheumatoid arthritis.
Scientists have found a way to target and knock out a protein which is widely involved in pancreatic cancer cell growth, survival and invasion.
Researchers have discovered a new combination therapy to treat drug-resistant acute lymphoblastic leukaemia, tested in pre-clinical trials.
An antibody has been developed to block a protein secreted by the cells surrounding ovarian and pancreatic cancer tumours.
Immunohistochemistry (IHC) and immunocytochemistry (ICC) are techniques employed to localize antigen expression and are dependent on specific epitope-antibody interactions.
The advent of in vitro culturing of neural cells has been central to driving our understanding of the nervous system.
Immune cell isolation and culture are necessary for both basic research aimed at investigating the functions of different immune cell types, and for expanding specific immune cell populations for therapeutic purposes.
A cellular pathway may reduce side effects and extend immunotherapy duration in patients with the most common form of liver cancer.
A study has revealed the role of a protein which enables human cytomegalovirus to spread, the number one cause of congenital birth defects in the world.
From the world’s flagship neutron science facility, Institut Laue-Langevin (ILL), Matthew Blakeley shares insights into how they are harnessing the power of neutrons to aid their search for new cancer treatments.